Elan Skelaxin FTC Inquiry Ongoing Despite Halt To Patent Listing Investigation

The Federal Trade Commission is continuing its inquiry into Elan's competitive practices for Skelaxin despite halting an investigation of whether the firm wrongfully listed a patent for the muscle relaxant